A positive trend in overall survival was observed, favoring sacituzumab govitecan over chemotherapy, though data is still ...
Dr. Strosberg discusses the safety profile and long-term toxicities of 212Pb-DOTAMTATE treatment, highlighting renal issues ...
In an interview with Targeted Oncology at the 2025 North American Neuroendocrine Tumor Society (NANETS) Symposium, Michael ...
The segment concludes that long-term data reinforce the durability and clinical relevance of combination immunotherapy, ...
A panelist discusses how both lurbinectedin and tarlatamab remain important in the management of relapsed small cell lung ...
The FDA accepted the investigational new drug application for UGN-103 in April 2024. These new positive data position the ...
Daratumumab and hyaluronidase-fihj received FDA approval for high-risk smoldering multiple myeloma, showing significant PFS ...
A panelist discusses how novel bispecifics and ADCs signal a more hopeful future for ES-SCLC management. A panelist discusses how the therapeutic landscape of extensive-stage small cell lung cancer ...
The DISCUS trial demonstrated improved QOL with 3 cycles of chemotherapy compared to 6 cycles in advanced urothelial cancer patients. Both treatment arms showed similar overall survival and ...
M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...
Jason S. Starr, DO, assistant professor of medicine and a hematologist/oncologist in the Department of Internal Medicine at ...
In the phase 2 EDGE-Gastric trial (NCT05329766), the combination of monoclonal antibodies domvanalimab and zimberelimab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback